Literature DB >> 15654830

Impaired interleukin (IL)-4-associated generation of CCR4-expressing T cells in neonates with hereditary allergy risk.

U Haddeland1, G B Sletten, P Brandtzaeg, B Nakstad.   

Abstract

Reduced microbial exposure in early life may contribute to the increase of atopic diseases in 'westernized' societies but the underlying mechanisms remain elusive. The objective of this study was to examine how exposure to bacterial lipopolysaccharide (LPS) during early antigen encounter might influence the maturation of neonatal lymphoid cells, and to define possible differences in this respect between neonates with high risk of allergy due to a family history (FH(+)) and controls with no apparent hereditary risk (FH(-)). Cord blood mononuclear cells from the FH(+) or FH(-) group were stimulated with pure LPS or beta-lactoglobulin (beta-LG) in the presence of LPS. T cell expression of chemokine receptors CCR4 and CXCR3 was determined by flow cytometry and reverse transcription-polymerase chain reaction (RT-PCR). Cellular expression of interleukin (IL)-4 was analysed by quantitative RT-PCR, whereas interferon (IFN)-gamma was analysed by both quantitative RT-PCR and immunoassay. Stimulation with LPS, or beta-LG together with LPS, induced up-regulation of CCR4 (P < 0.05) and CXCR3 (P < 0.05). For CCR4, such up-regulation was related to the level of IL-4 produced by the same T cells (r(S) = 0.49, P = 0.03), while CXCR3 expression was negatively correlated with the IL-4 levels (r(S) = -0.56, P = 0.02). Compared with the FH(-) group, the FH(+) group showed a significantly lower capacity for generation of CCR4(+) T cells (mean percentage of total T cells: FH(+), 2.42%versus FH(-), 5.74%; P < 0.01), whereas induction of CXCR3 and IFN-gamma did not differ significantly between the two groups. When the immune system in early life encounters antigen together with LPS, the T cell potential for compartmentalized interaction with other immune cells might be increased by elevated CCR4- and CXCR3-expression levels. In neonates at hereditary allergy risk, this putative homeostatic mechanism could theoretically be jeopardized due to decreased up-regulation of CCR4. Conversely, Th1 responses to antigen in the presence of LPS did not appear to be reduced compared with controls.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15654830      PMCID: PMC1809286          DOI: 10.1111/j.1365-2249.2005.02706.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Exposure to pets and atopy-related diseases in the first 4 years of life.

Authors:  P Nafstad; P Magnus; P I Gaarder; J J Jaakkola
Journal:  Allergy       Date:  2001-04       Impact factor: 13.146

Review 2.  The role of chemokine receptors in primary, effector, and memory immune responses.

Authors:  F Sallusto; C R Mackay; A Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-gamma, IL-4 and IL-10.

Authors:  V H van der Velden; M P Laan; M R Baert; R de Waal Malefyt; H J Neijens; H F Savelkoul
Journal:  Clin Exp Allergy       Date:  2001-07       Impact factor: 5.018

4.  Exposure to endotoxin or other bacterial components might protect against the development of atopy.

Authors:  E von Mutius; C Braun-Fahrländer; R Schierl; J Riedler; S Ehlermann; S Maisch; M Waser; D Nowak
Journal:  Clin Exp Allergy       Date:  2000-09       Impact factor: 5.018

5.  The murine beta-chemokine TARC is expressed by subsets of dendritic cells and attracts primed CD4+ T cells.

Authors:  I Lieberam; I Förster
Journal:  Eur J Immunol       Date:  1999-09       Impact factor: 5.532

6.  Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma.

Authors:  J E Gereda; D Y Leung; A Thatayatikom; J E Streib; M R Price; M D Klinnert; A H Liu
Journal:  Lancet       Date:  2000-05-13       Impact factor: 79.321

7.  Prevalence of respiratory and atopic disorders among children in the East and West of Germany five years after unification.

Authors:  S K Weiland; E von Mutius; T Hirsch; H Duhme; C Fritzsch; B Werner; A Hüsing; M Stender; H Renz; W Leupold; U Keil
Journal:  Eur Respir J       Date:  1999-10       Impact factor: 16.671

8.  Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey.

Authors:  J Riedler; C Braun-Fahrländer; W Eder; M Schreuer; M Waser; S Maisch; D Carr; R Schierl; D Nowak; E von Mutius
Journal:  Lancet       Date:  2001-10-06       Impact factor: 79.321

Review 9.  Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression?

Authors:  U Syrbe; J Siveke; A Hamann
Journal:  Springer Semin Immunopathol       Date:  1999

10.  Cutting edge: CCR4 mediates antigen-primed T cell binding to activated dendritic cells.

Authors:  M Wu; H Fang; S T Hwang
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

View more
  3 in total

1.  IFN-gamma and STAT1 are required for efficient induction of CXC chemokine receptor 3 (CXCR3) on CD4+ but not CD8+ T cells.

Authors:  Joseph Barbi; Steve Oghumu; Claudio M Lezama-Davila; Abhay R Satoskar
Journal:  Blood       Date:  2007-09-15       Impact factor: 22.113

2.  Prenatal stress, anxiety and depression alter transcripts, proteins and pathways associated with immune responses at the maternal-fetal interface†.

Authors:  Cristina A Martinez; Ina Marteinsdottir; Ann Josefsson; Gunilla Sydsjö; Elvar Theodorsson; Heriberto Rodriguez-Martinez
Journal:  Biol Reprod       Date:  2022-03-19       Impact factor: 4.285

3.  Early detection of neonatal group B streptococcus sepsis and the possible diagnostic utility of IL-6, IL-8, and CD11b in a human umbilical cord blood in vitro model.

Authors:  Britt Nakstad; Tonje Sonerud; Anne Lee Solevåg
Journal:  Infect Drug Resist       Date:  2016-07-08       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.